Sam Horng, MD, PhD, and PGY3 resident in the Department of Neurology has been approved for funding under the Mount Sinai R25 Research Residency Program. The Program provides mentoring and dedicated time set aside for research during residency and fellowship years.
An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.
The Mount Sinai Hospital is one of three institutions in New York State, and one of one hundred in the nation, selected to study the safety and effectiveness of an implantable cranial nerve stimulation device for heart failure patients with debilitating fatigue, shortness of breath, and heart arrhythmias.
A recent NBC News article highlighted the importance of genetic research and the potential therapeutic application of histamine for individuals with Tourette Syndrome (TS). TS is a chronic neuropsychiatric disorder characterized by multiple motor and vocal tics. Onset of tics occurs before age 18 and is often associated with marked impairment and disability.
Mounting evidence suggests that age-related cognitive decline is caused not by nerve cell death, as it is in Alzheimer’s disease, but from a disruption in synapses, the structures that allow a nerve cell to transmit a signal to other nerve cells. Demonstrating these synaptic disruptions in the prefrontal cortex of the brain, and linking such disruptions to synaptic health, has been challenging for scientists—until now.
The creation of a trachea engineered from stem cells that can be transplanted in people with lung or airway diseases is being pioneered by physicians at St. Luke’s and Roosevelt Hospitals. The promising technology will be presented at the Society of Thoracic Surgeons 50th Annual Meeting in Orlando in late January by a team led by Faiz Bhora, MD, Director of Thoracic Surgical Oncology and Thoracic Surgery Research at St. Luke’s and Roosevelt Hospitals.